The global Advanced Therapy Medicinal Products CDMO Market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of cell therapies, gene therapies, and regenerative medicines. Contract development and manufacturing organizations provide specialized capabilities covering process development, viral-vector manufacturing, analytical testing, clinical manufacturing, regulatory support, and commercial-scale production. Increasing clinical-trial activity, rising approvals of advanced therapies, and the growing complexity of manufacturing processes are strengthening demand for specialized CDMO partners.
According to Fortune Business Insights, the global advanced therapy medicinal products CDMO market was valued at USD 8.15 billion in 2025 and is projected to grow from USD 9.72 billion in 2026 to USD 39.75 billion by 2034, exhibiting a CAGR of 19.24% during the forecast period.
Why is the Advanced Therapy Medicinal Products CDMO Market Growing?
The increasing development of cell and gene therapies is one of the strongest growth drivers. Advanced therapies often require specialized manufacturing systems, highly controlled environments, sophisticated analytical testing, and extensive regulatory support that may be difficult or costly for therapy developers to build internally.
CDMOs are increasingly supporting:
- Gene therapy manufacturing
- Cell therapy manufacturing
- Viral-vector production
- Process development
- Analytical testing
- Clinical batch manufacturing
- Commercial manufacturing
- Regulatory support
- Quality control
- Cold-chain and logistics services
The growing number of clinical programs and advanced-therapy approvals is encouraging biotechnology companies and pharmaceutical manufacturers to establish long-term partnerships with specialized CDMOs.
Key Market Trends Shaping Industry Growth
Increasing Demand for Integrated CDMO Services
A major market trend is the shift toward end-to-end CDMO solutions. Providers are increasingly offering process development, analytical testing, clinical manufacturing, commercial production, regulatory consulting, and logistics under integrated service models.
This integrated approach allows therapy developers to reduce operational complexity and manage multiple stages of development through a single manufacturing partner.
Expansion of Viral Vector Manufacturing
Demand for adeno-associated virus, lentivirus, and retrovirus manufacturing is increasing as gene therapy pipelines expand. CDMOs are investing in dedicated vector-production facilities and improved purification and analytical technologies to address growing demand.
Growing Adoption of Automation and Digital Manufacturing
Automation, digital manufacturing systems, and AI-based process optimization are becoming increasingly important in advanced-therapy production. These technologies can improve manufacturing consistency, process monitoring, and production efficiency.
Increasing Use of Single-Use Bioprocessing
Single-use technologies are gaining adoption because they can provide greater manufacturing flexibility and help reduce contamination risks. This approach is particularly valuable for smaller-batch and personalized therapies.
Expansion of Personalized Medicine
Personalized and patient-specific therapies are creating demand for agile, flexible, and scalable manufacturing models. CDMOs are investing in modular facilities and digital manufacturing systems to support smaller production batches and shorter turnaround requirements.
Growing Strategic Partnerships
Biotechnology companies and pharmaceutical manufacturers are increasingly entering partnerships with specialized CDMOs to secure manufacturing capacity and specialized expertise. These collaborations can support development from early-stage research through commercialization.
Market Dynamics
Driver: Rising Demand for Cell and Gene Therapies
The rapidly expanding pipeline of cell and gene therapies is the primary driver of the market. These therapies are being developed for rare diseases, inherited disorders, oncology, neurological conditions, and other complex diseases.
Manufacturing advanced therapies requires specialized facilities, trained personnel, stringent quality controls, and sophisticated analytical systems. Outsourcing can help therapy developers access these capabilities while reducing the need for large in-house investments.
Restraint: Complex Regulatory and Manufacturing Requirements
Advanced therapies require highly controlled manufacturing environments, extensive documentation, rigorous quality assurance, and continuous process validation. These requirements increase development costs and operational complexity.
Differences in regulatory frameworks across regions can also complicate multinational manufacturing programs.
Opportunity: Expansion of Personalized Medicine
Personalized medicine represents a major opportunity for specialized CDMOs. Patient-specific therapies frequently require smaller batch sizes, flexible manufacturing systems, rapid turnaround, and highly controlled production processes.
Applications in oncology, rare diseases, regenerative medicine, and immunotherapy are creating additional manufacturing opportunities.
Challenge: Skilled Workforce Shortages
Advanced therapy manufacturing requires expertise across molecular biology, virology, bioprocess engineering, quality assurance, and regulatory compliance. The shortage of highly qualified professionals can limit production efficiency and delay facility expansion.
CDMOs and therapy developers are therefore increasing investments in workforce training and partnerships with academic institutions.
For detailed market insights: https://www.fortunebusinessinsights.com/advanced-therapy-medicinal-products-cdmo-market-116715
Market Segmentation Analysis
By Product
Gene Therapy Segment Dominates
The Gene Therapy segment accounts for approximately 58% of the global market.
Demand is being driven by increasing development of therapies targeting:
- Inherited genetic disorders
- Rare diseases
- Neurological disorders
- Oncology
- Other serious chronic conditions
Gene therapy manufacturing requires specialized viral-vector production, analytical testing, process optimization, scale-up, and regulatory support, making experienced CDMOs strategically important to developers.
Cell Therapy Segment
The Cell Therapy segment accounts for approximately 42% of the market. It includes autologous and allogeneic therapies for oncology, autoimmune disorders, regenerative medicine, and tissue-repair applications.
Cell therapy manufacturing requires sophisticated cell handling, expansion, cryopreservation, quality testing, and patient-specific production capabilities. Growing adoption of CAR-T therapies and regenerative medicine is supporting the segment.
By Phase
The Phase-based Manufacturing Services segment accounts for approximately 55% of the market. It includes manufacturing support for preclinical, Phase I, Phase II, and Phase III development programs.
CDMOs support these programs through:
- Process development
- Analytical testing
- Quality control
- Clinical batch manufacturing
- Scale-up
- Regulatory support
The growing number of advanced-therapy clinical trials is increasing demand for manufacturing partners capable of supporting programs throughout development.
By Indication
Indication-Based Manufacturing Services
Indication-based manufacturing services represent approximately 45% of the market. This category includes manufacturing programs for:
- Oncology
- Rare diseases
- Neurological disorders
- Cardiovascular diseases
- Autoimmune disorders
Oncology remains the largest therapeutic area because of extensive development activity involving cell and gene therapies.
The increasing prevalence of chronic and genetic disorders is encouraging pharmaceutical and biotechnology companies to expand advanced-therapy pipelines.
Regional Insights
North America Leads the Global Market
North America held approximately 41% of the global Advanced Therapy Medicinal Products CDMO Market. The region benefits from a highly developed biotechnology ecosystem, significant research funding, strong intellectual-property protection, and a large concentration of therapy developers.
The United States remains the largest center for advanced-therapy manufacturing and commercialization. Strong clinical-trial activity, FDA-supported development pathways, venture-capital investment, and expanding manufacturing infrastructure are strengthening regional demand.
Europe
Europe accounted for approximately 29% of the global market. Strong biotechnology research, supportive healthcare policies, advanced manufacturing capabilities, and growing interest in regenerative medicine are supporting regional growth.
Germany represents approximately 28% of Europe's market, while the U.K. accounts for approximately 24%.
Asia Pacific
Asia Pacific accounted for approximately 22% of the global market and is emerging as a rapidly expanding advanced-therapy manufacturing region. Growing biotechnology investment, improving healthcare infrastructure, and increasing clinical-research activity are supporting market development.
Competitive Landscape
The global Advanced Therapy Medicinal Products CDMO Market is competitive, with leading contract development and manufacturing organizations expanding their capabilities in cell therapy, gene therapy, viral-vector production, process development, analytical testing, and commercial manufacturing. According to Fortune Business Insights, Lonza holds approximately 16% of the global market share, followed by Catalent with approximately 13%.
Major Companies Operating in the Market
- Celonic
- Bio Elpida
- CGT Catapult
- Rentschler Biopharma SE
- AGC Biologics
- Catalent
- Lonza
- WuXi Advanced Therapies
- BlueReg
- Minaris Regenerative Medicine
- Patheon
Investment Analysis and Opportunities
The Advanced Therapy Medicinal Products CDMO Market is attracting significant investment as biotechnology companies and pharmaceutical manufacturers seek specialized manufacturing partners for increasingly complex cell and gene therapies.
Investment is focused on viral-vector manufacturing, cell-processing facilities, automation, digital manufacturing, analytical testing, quality-control systems, and scalable commercial production. CDMOs that can provide integrated development-to-commercialization services are particularly well positioned to benefit from increasing outsourcing.
Key Investment Opportunities
- Viral-vector manufacturing
- Gene therapy CDMO services
- Cell therapy manufacturing
- Allogeneic cell therapy
- Autologous therapy production
- Automated cell processing
- Single-use bioprocessing
- Advanced analytical testing
- Digital quality-management systems
- Cryopreservation and specialty logistics
- Personalized medicine manufacturing
The expansion of oncology, rare-disease, regenerative-medicine, and immunotherapy pipelines is creating additional opportunities for specialized CDMO providers.
New Product Development
Innovation in the Advanced Therapy Medicinal Products CDMO Market is increasingly focused on improving scalability, manufacturing consistency, automation, and quality control.
Key areas of development include:
- Advanced viral-vector production platforms
- Automated cell-processing systems
- Closed-system manufacturing
- AI-assisted process monitoring
- Digital quality-management platforms
- Next-generation analytical testing
- Allogeneic cell-therapy manufacturing
- Scalable gene-therapy production
- Advanced cryopreservation technologies
- Temperature-controlled logistics solutions
CDMOs are also developing more flexible manufacturing models that can support smaller patient-specific batches while maintaining strict quality standards.
Five Recent Industry Developments 2023–2025
According to Fortune Business Insights, notable developments include:
- Lonza expanded advanced-therapy manufacturing capacity through facility upgrades focused on cell and gene therapy production.
- Catalent strengthened viral-vector manufacturing capabilities through strategic infrastructure investments.
- AGC Biologics expanded its global cell-therapy manufacturing operations to support growing client demand.
- WuXi Advanced Therapies enhanced integrated development and manufacturing service capabilities.
- Minaris Regenerative Medicine increased production capacity for regenerative medicine and cell-therapy applications.
Request Sample Report
Future Outlook
According to Fortune Business Insights, the global Advanced Therapy Medicinal Products CDMO Market was valued at USD 8.15 billion in 2025 and is projected to grow from USD 9.72 billion in 2026 to USD 39.75 billion by 2034, exhibiting a CAGR of 19.24% during the forecast period.
Increasing Demand for Gene Therapy Manufacturing
The Gene Therapy segment accounts for approximately 58% of the market and remains the largest product segment. Growing development of treatments for rare diseases, genetic disorders, neurological conditions, and cancer is increasing demand for viral-vector manufacturing and specialized analytical services.
Expansion of Cell Therapy Manufacturing
The Cell Therapy segment accounts for approximately 42% of the market. The development of autologous and allogeneic therapies, CAR-T treatments, regenerative medicine, and immunotherapies is creating increasing demand for specialized cell-processing and manufacturing capabilities.
Growth of Integrated CDMO Services
End-to-end services covering process development, analytical testing, clinical manufacturing, commercial production, regulatory consulting, and logistics are expected to gain further adoption.
These integrated models allow therapy developers to reduce operational complexity and use a single specialized partner across multiple development stages.
Expansion of Viral-Vector Capacity
The growing pipeline of gene therapies is increasing demand for AAV, lentiviral, and retroviral vector production. CDMOs are investing in dedicated facilities, improved purification processes, and advanced analytical technologies to address capacity and quality requirements.
Increasing Adoption of Automation and Digital Manufacturing
Automation, digital process monitoring, and AI-assisted manufacturing are expected to improve consistency, scalability, process control, and operational efficiency.
Digital quality systems can also help CDMOs manage the extensive documentation and data requirements associated with advanced therapies.
Growth of Personalized Medicine
Personalized and patient-specific therapies are creating demand for flexible manufacturing models capable of supporting smaller production batches and rapid turnaround.
Modular facilities, closed manufacturing systems, and advanced cryopreservation technologies are expected to become increasingly important.
Increasing Strategic Partnerships
Biotechnology companies and pharmaceutical manufacturers are increasingly establishing long-term relationships with specialized CDMOs to secure manufacturing capacity and technical expertise.
These partnerships are expected to become increasingly important as therapies progress from early clinical stages toward commercialization.
Regional Growth Opportunities
North America held approximately 41% of the global market in 2025, followed by Europe at 29%, Asia Pacific at 22%, and the Rest of the World at 8%.
North America
North America remains the leading regional market due to its large biotechnology ecosystem, extensive research funding, advanced manufacturing infrastructure, and high concentration of cell and gene therapy developers.
The United States is the principal contributor, supported by strong clinical-trial activity, biotechnology investment, advanced CDMO infrastructure, and an established regulatory environment.
Europe
Europe accounts for approximately 29% of the global market. Strong biotechnology research, advanced manufacturing infrastructure, regulatory expertise, and growing regenerative-medicine activity are supporting regional demand.
Germany represents approximately 28% of Europe's market, while the U.K. accounts for approximately 24%.
Asia Pacific
Asia Pacific represents approximately 22% of the global market and is expanding as governments and private companies invest in biotechnology, healthcare infrastructure, and advanced-therapy manufacturing.
Japan represents approximately 11% of the Asia Pacific market, while China accounts for approximately 9%.
Rest of the World
The Rest of the World accounts for approximately 8% of the market. Developing biotechnology infrastructure, international partnerships, technology-transfer programs, and increasing healthcare investment are creating emerging opportunities across Latin America, the Middle East, and Africa.
Overall, gene therapy manufacturing, cell therapy, viral-vector production, integrated CDMO services, automation, personalized medicine, and advanced analytical technologies are expected to remain the major growth areas for the global Advanced Therapy Medicinal Products CDMO Market through 2034.
What’s Driving Japan’s Market? Discover the Latest Advanced Therapy Medicinal Products CDMO Market Insights
この記事をシェア
